VWF concentrate administration
| VWF concentrate option . | Description . |
|---|---|
| VWF/FVIII concentrate (plasma derived) | Plasma-derived concentrate containing both VWF and FVIII; administered IV; typical dosing: 40-80 VWF/RCo activity units per kg |
| VWF concentrate (plasma derived) | Plasma-derived concentrate containing VWF alone; administered IV; typical dosing: 40-80 VWF/RCo activity units per kg; if used for emergency treatment, may require addition of FVIII concentrate in patients with low baseline FVIII |
| VWF concentrate (recombinant) | Recombinant concentrate containing VWF alone; administered IV; typical dosing: 40-80 VWF/RCo activity units per kg; if used for emergency treatment, may require addition of FVIII concentrate in patients with low baseline FVIII |
| VWF concentrate option . | Description . |
|---|---|
| VWF/FVIII concentrate (plasma derived) | Plasma-derived concentrate containing both VWF and FVIII; administered IV; typical dosing: 40-80 VWF/RCo activity units per kg |
| VWF concentrate (plasma derived) | Plasma-derived concentrate containing VWF alone; administered IV; typical dosing: 40-80 VWF/RCo activity units per kg; if used for emergency treatment, may require addition of FVIII concentrate in patients with low baseline FVIII |
| VWF concentrate (recombinant) | Recombinant concentrate containing VWF alone; administered IV; typical dosing: 40-80 VWF/RCo activity units per kg; if used for emergency treatment, may require addition of FVIII concentrate in patients with low baseline FVIII |
RCo, ristocetin cofactor.